Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Senaparib first-line maintenance in BRCAwt advanced ovarian-related cancers
ChiCTR2600117526Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of senaparib in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Safety (adverse event incidence). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
senaparib
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ChiCTR2600117526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117526.